TP Therapeutics Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- TP Therapeutics's estimated annual revenue is currently $11.8M per year.
- TP Therapeutics received $80.0M in venture funding in October 2018.
- TP Therapeutics's estimated revenue per employee is $145,432
- TP Therapeutics's total funding is $144.4M.
- TP Therapeutics has 81 Employees.
- TP Therapeutics grew their employee count by 145% last year.
- TP Therapeutics currently has 15 job openings.
|Miriam Cruz||Vice President Clinical Operations, Oncology|
|Dayong Zhai||Director, Biology|
|Yuelie Lu||Vice President, CMC Operations|
|Jessica Crane||Director Clinical Operations|
|Robert Xin||SVP, Clinical Development|
|John Huang||Executive Director of Translational Research|
|Armin Graber||Vice President Of Companion Diagnostics & Biomarkers|
|Susan Martin||Executive Assistant To Chief Executive Officer|
|Denise Leone||Director, Biostatistics and Programming|
|Junming Zhu||Sr. Director of Biostatistics and Data Management|
What Is TP Therapeutics?
TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. Our lead therapeutic project, TPX-0005, is in clinical development (TRIDENT-1). TP- Turning Point Medicines for Life!keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$25.7M||178||8%||N/A|
|Full Spectrum A...||$6M||42||5%||N/A|
TP Therapeutics News
Roche has won US Food and Drug Administration (FDA) approval for its rival to Bayer's oncology drug Vitrakvi (larotrectinib). The approval ...
ATR of the company Amicus Therapeutics, Inc., stands at 0.46 while a Beta ... Target pricing (TP) at which a trader projects that a buyer will ...
Sarepta Therapeutics, Inc., belongs to the Healthcare sector and ... Analyst's mean target price(TP) for the company is 210.45 while analysts ...
TP Therapeutics Funding
|2017-05-24||$45.0M||C||Lilly Asia Ventures||Article|
TP Therapeutics Executive Hires
|2017-12-05||Sheila Gujrathi||Strategic Advisor||Article|
|2018-05-15||Athena Countouriotis||EVP/Chief Medical Officer||Article|
|2019-01-29||Robert Xin||SVP Clinical Development||Article|
|2019-03-26||Jim Mazzola||Lead Corporate Communication and Investor Relations||Article|